{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:14:08Z","timestamp":1782285248352,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Different risk factors may influence the effectiveness of osteoporosis therapies. The interaction of 30 baseline risk factors and the effectiveness of raloxifene in the MORE study were assessed. The efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures.<\/jats:p>\n               <jats:p>Introduction: The aim of this analysis was to determine the effect of different risk factors on the effectiveness of raloxifene to reduce vertebral fractures in the Multiple Outcomes of Raloxifene Evaluation (MORE) study using logistic regression models.<\/jats:p>\n               <jats:p>Materials and Methods: The association was assessed using univariate analyses and a multivariate model between 30 potential risk factors at baseline and the risk of vertebral fractures after 3 years in the placebo group, as well as the interaction of risk factors with raloxifene therapy (at a dose of 60 or 120 mg\/day).<\/jats:p>\n               <jats:p>Results and Conclusions: In the univariate analysis of the placebo group, after adjusting for baseline lumbar spine BMD (LS BMD), short stature (odds ratio [OR] = 1.18), age (OR = 1.38), years since menopause (OR = 1.38), impaired cognitive function, visuospatial capabilities (OR = 1.19), impaired musculoskeletal strength (OR = 1.23), low femoral neck BMD (OR = 1.21), and prior vertebral fracture (OR = 4.95) were significantly associated with the incidence of new vertebral fractures. In the univariate analysis, significant interactions were observed between raloxifene treatment and age (p = 0.04), serum triglycerides (p = 0.03), LS BMD (p = 0.08), and diabetes mellitus (p = 0.04). In the multivariate analysis, the effectiveness of raloxifene was independent of almost all risk factors, with the exception of baseline serum triglyceride level and LS BMD, suggesting an increased efficacy of raloxifene in patients with increased triglyceride levels (p = 0.006) and lower LS BMD values (p = 0.008) at baseline. These data suggest that the efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures.<\/jats:p>","DOI":"10.1359\/jbmr.040211","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T07:02:13Z","timestamp":1146121333000},"page":"764-772","source":"Crossref","is-referenced-by-count":101,"title":["Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study"],"prefix":"10.1093","volume":"19","author":[{"given":"Olof","family":"Johnell","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Malm\u00f6 General Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Kanis","sequence":"additional","affiliation":[{"name":"WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M","family":"Black","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Balogh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Poor","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatology and Physiotherapy, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019205386900_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 4","key":"2024013019205386900_bib2","first-page":"S1","article-title":"Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis","volume":"8","author":"National Osteoporosis Foundation","year":"1988","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","article-title":"Guidelines for diagnosis and management of osteoporosis","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S8756-3282(01)00653-6","article-title":"Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies","volume":"30","author":"Kanis","year":"2002","journal-title":"Bone"},{"key":"2024013019205386900_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"2024013019205386900_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2024013019205386900_bib7","first-page":"1046","article-title":"Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease","volume":"77","author":"Garnero","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205386900_bib8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jbmr.5650071206","article-title":"Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay","volume":"7","author":"Garnero","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013019205386900_bib9","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"key":"2024013019205386900_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"2024013019205386900_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM200104193441604","article-title":"Cognitive function in postmenopausal women treated with raloxifene","volume":"344","author":"Yaffe","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019205386900_bib12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","article-title":"Validation of a short Orientation-Memory-Concentration Test of cognitive impairment","volume":"140","author":"Katzman","year":"1983","journal-title":"Am J Psychiatry"},{"key":"2024013019205386900_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"2024013019205386900_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1192\/bjp.123.4.467","article-title":"The Set test as an aid to the detection of dementia in old people","volume":"123","author":"Isaacs","year":"1973","journal-title":"Br J Psychiatry"},{"key":"2024013019205386900_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1532-5415.1993.tb06708.x","article-title":"Development of the common data base for the FICSIT trials","volume":"41","author":"Buchner","year":"1993","journal-title":"J Am Geriatr Soc"},{"key":"2024013019205386900_bib16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/jbmr.5650110510","article-title":"Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts","volume":"11","author":"Lu","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019205386900_bib17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019205386900_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000"},{"key":"2024013019205386900_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00198-002-1317-8","article-title":"Determinants of incident vertebral fracture in men and women: Results from the European Prospective Osteoporosis Study (EPOS)","volume":"14","author":"Roy","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib20","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00007632-199712151-00002","article-title":"Epidemiology of spinal osteoporosis","author":"Melton","year":"1997","journal-title":"Spine"},{"key":"2024013019205386900_bib21","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"Suppl 6","key":"2024013019205386900_bib22","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib23","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1210\/jcem.86.9.7848","article-title":"Influence of smoking on the antiosteoporotic efficacy of raloxifene","volume":"86","author":"Chapurlat","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205386900_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jama.287.2.216","article-title":"Serum estradiol level and risk of breast cancer during treatment with raloxifene","volume":"287","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"2024013019205386900_bib25","first-page":"S1;S414","article-title":"Relationship between age and prior use of HRT on vertebral fracture risk reduction with raloxifene in postmenopausal women: Results from the MORE trial","volume":"16","author":"Johnell","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019205386900_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019205386900_bib27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s001980170031","article-title":"Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature","volume":"12","author":"Espallargues","year":"2001","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","article-title":"Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group","volume":"159","author":"Kado","year":"1999","journal-title":"Arch Intern Med"},{"key":"2024013019205386900_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001980050138","article-title":"Number and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group","volume":"9","author":"Ismail","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019205386900_bib31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: An observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"2024013019205386900_bib32","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"2024013019205386900_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"2024013019205386900_bib34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"Suppl 103","key":"2024013019205386900_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03009749609103770","article-title":"Risk factors of osteoporosis: Results of EVOS in Germany","volume":"25","author":"Janott","year":"1996","journal-title":"Scand J Rheumatol"},{"key":"2024013019205386900_bib36","first-page":"394","author":"Wasnich","year":"1987"},{"key":"2024013019205386900_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF01623464","article-title":"Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women","volume":"7","author":"O'Neill","year":"1997","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.040211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/764\/56476204\/5650190511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/764\/56476204\/5650190511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:41Z","timestamp":1710342401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/5\/764-772\/7592953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040211","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,5,1]]},"published":{"date-parts":[[2004,5,1]]}}}